Where does Immunomic Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Immunomic Therapeutics, Inc. ranks #32,022 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Immunomic Therapeutics, Inc. hold?

Immunomic Therapeutics, Inc. holds 8 US utility patents granted between 2017 and 2025, spanning 4 technology areas.

What is Immunomic Therapeutics, Inc.'s Innovation Score?

Immunomic Therapeutics, Inc. has an Innovation Score of 48.8 out of 100 (top 16% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Immunomic Therapeutics, Inc. focus on?

Immunomic Therapeutics, Inc.'s top technology area is C07K (Peptides) with 8 patents. Grants appear in 4 CPC subclasses total.

Is Immunomic Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Immunomic Therapeutics, Inc.'s recent grant velocity is +100% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Immunomic Therapeutics, Inc.'s patents?

Immunomic Therapeutics, Inc.'s patents average 23.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Immunomic Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Immunomic Therapeutics, Inc.

USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Immunomic ranks #32,022 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.

#32,022
of 49,997 US assignees by volume: Top 16%
by Innovation Score (48.8/100): 23.6
avg claims per patent: +100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32022 · US Corporation #32,022 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,022/49,997
PHOTO-FINISH ImageWare Systems
CPC-NARROW C07K · 4 areas
INNOV-PAR 48.8/100
CLAIMS-DENSE 23.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ImageWare Systems Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Immunomic Therapeutics · this assignee

49
3D Lighting… · lowest

7

What this shows Immunomic's Innovation Score is 48.8/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Immunomic's grants concentrate

Immunomic Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2017. By volume, Immunomic sits between ImageWare Systems Inc. and Implicit, LLC.

Immunomic's three-year grant acceleration

Immunomic Therapeutics, Inc. shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Imageware Systems

8
Imerys Filtration…

8
Immatics US

8
Immunext

8
Imperative Chemic…

8
Imperial Pools

8
Implant Sciences

8
Implicit

8
Immunomic Therape… ◀

8

What this shows Immunomic holds 8 patents at rank #32,077, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Immunomic

By rank, the assignees closest to #32,077 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Immunomic's primary technology class.

Immunomic's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Immunomic Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	12.5%
2018	1	12.5%
2021	1	12.5%
2023	2	25.0%
2024	1	12.5%
2025partial year	2	25.0%

Which technologies does Immunomic Therapeutics, Inc. patent most?

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

Y02A - Technologies FOR Adaptation TO Climate Change 4

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#32,022

of 49,997 tracked assignees

Innovation Score

48.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Immunomic Therapeutics, Inc.'s patent record in context - here's where to go next.

Immunomic Therapeutics, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #32,022 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Immunomic Therapeutics, Inc. against ImageWare Systems Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.